RESTATEMENT (Details 1) - USD ($)	3 Months Ended						9 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2020	Jun. 30, 2019
Research and development expenses	$ 3,969,070			$ 2,965,512			$ 12,680,430	$ 9,269,772
Total operating expenses	7,161,473			5,319,037			21,070,251	14,937,282
Operating loss	(6,965,599)			(5,210,099)			(20,540,145)	(14,551,161)
Net loss	$ (10,276,979)	$ (9,067,818)	$ (5,531,360)	$ (12,084,768)	$ (6,447,681)	$ 1,245,902	(24,876,157)	(17,286,547)
Net loss available to common shareholders							$ (24,876,157)	$ (17,286,547)
Net loss per share - basic and diluted	$ (0.27)			$ (0.37)			$ (0.69)	$ (0.58)
Previously Reported [Member]
Research and development expenses	$ 3,912,870						$ 12,511,830
Total operating expenses	7,105,273						20,901,651
Operating loss	(6,909,399)						(20,371,545)
Net loss							(24,707,557)
Net loss available to common shareholders	$ (10,220,779)						$ (24,729,291)
Net loss per share - basic and diluted	$ (0.27)						$ (0.68)
Adjustment [Member]
Research and development expenses	$ 56,200						$ 168,600
Total operating expenses	56,200						168,600
Operating loss	(56,200)						(168,600)
Net loss							(168,600)
Net loss available to common shareholders	(56,200)						(168,600)
Restated [Member]
Research and development expenses	3,969,070						12,680,430
Total operating expenses	7,161,473						21,070,251
Operating loss	(6,965,599)						(20,540,145)
Net loss							(24,876,157)
Net loss available to common shareholders	$ (10,276,979)						$ (24,897,891)
Net loss per share - basic and diluted	$ (0.27)						$ (0.69)